59 search results for: mechanism of disease

COPD and Asthma: What's the Difference and Is There a Link?
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

Pulmonology
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
View more
Impact <b>of</b> Advanced Systemic Therapies on <b>Disease</b> Control in AD
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Dermatology
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Neuroimmune Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>
Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Dermatology
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
View more
PN is Considered a Unique Clinical Entity Distinct from Other Pruritic <b>Disease</b>s and Psychiatric Conditions
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Dermatology
Dr. Sarina Elmariah discusses PN being a unique clinical entity, distinct from other pruritic diseases and psychiatric conditions.
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Dermatology
Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.
View more
Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?
expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
ERS 2024 | Pathophysiologic <b>Mechanism</b>s <b>of</b> Airway Remodeling in Severe Asthma
expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

Pulmonology
Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region